BioCapital

Found 41,426 articles

• 

  BioSpace Launches 2022 Hotbed Maps to Highlight Thriving Life Sciences Clusters

  1/18/2022

  As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.

• Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose

  2/3/2023

  Orexo AB, announces the submission of a New Drug Application to the US Food and Drug Administration for its lead pharmaceutical pipeline asset, OX124, a nasal rescue medication for opioid overdose.

• TEZSPIRE® approved for self-administration in the US with a new pre-filled pen

  2/2/2023

  AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) has been approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.

• Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants - February 02, 2023

  2/2/2023

  Avalo Therapeutics, Inc. announced that it has commenced a proposed underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock.

• Gain Therapeutics to Participate in Upcoming Scientific and Medical ConferencesGain to present new preclinical data on its lead programs in GBA1-related diseases

  2/2/2023

  Gain Therapeutics, Inc. today announced that the Company will present new preclinical data at the following upcoming scientific and medical meetings.

• Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants

  2/2/2023

  Avalo Therapeutics, Inc. (NASDAQ: AVTX) (Avalo) announced today the pricing of an underwritten public offering of 3,770,000 shares of its common stock and warrants to purchase up to an aggregate of 3,770,000 shares of common stock, at a price to the public of $3.98 per share and warrant.

• FDA Approves First Oral Treatment for Anemia Caused by Chronic Kidney Disease for Adults on Dialysis

  2/1/2023

  Today, the U.S. Food and Drug Administration approved Jesduvroq tablets (daprodustat) as the first oral treatment for anemia (decreased number of red blood cells) caused by chronic kidney disease for adults who have been receiving dialysis for at least four months.

• Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers

  2/1/2023

  Sirnaomics Ltd. announced that it is advancing the clinical development of STP705 for the treatment of two non-melanoma skin cancers: Squamous Cell Carcinoma in situ and Basal Cell Carcinoma.

• Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed

  2/1/2023

  Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) today announced it has entered into an option agreement for the sale of the assets of Purnovate, Inc. (“Purnovate”), a wholly owned subsidiary of Adial, to Adenomed, LLC (“Adenomed”), a new company formed by Purnovate CEO, William Stilley, founder and former CEO of Adial.

• MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences

  2/1/2023

  MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) today announced that it will release financial results for the fourth quarter and full year 2022 after the U.S. market close on Wednesday, March 15th, 2023.

• Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 8, 2023

  2/1/2023

  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2022 on Wednesday, February 8, 2023, after the market closes.

• The American Diabetes Association Announces 2023 Pathway to Stop Diabetes Grant Recipients

  1/31/2023

  The American Diabetes Association® announced the two winners of the Pathway to Stop Diabetes® grants, a five-year grant to support breakthroughs in translational science, clinical science, technology, care, and potential cures in the field of diabetes.

• Biomanufacturing Company Vector BioMed Launches with Mission to Provide Access to High-Quality Lentiviral Vectors and Address the Vector Supply Bottleneck

  1/31/2023

  Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, today announced its launch and first financing round led by Viking Global Investors and Casdin Capital.

• AMPEL BioSolutions' Breakthrough Predicts Drug Options for Fibromyalgia

  1/31/2023

  AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat chronic pain syndromes, such as fibromyalgia.

• Rise Therapeutics Announces FDA Clearance of its IND Application to Initiate a Phase 1 Study of an Oral Immunotherapy for the Treatment of Ulcerative Colitis

  1/31/2023

  Rise Therapeutics, a biopharmaceutical company engaged in developing novel oral synthetic biology medicines, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a Phase 1 clinical trial of its lead program candidate, R-3750.

• Thymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapy

  1/31/2023

  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is reporting today a new scientific publication describing Thymosin beta 4's (Tβ4) potential as an anti-aging therapy.

• Evolent Health, Inc. to Release Fourth Quarter Financial Results and Host Conference Call on Wednesday, February 22, 2023

  1/31/2023

  Evolent Health, Inc. (NYSE: EVH) today announced it will release its fourth quarter 2022 financial results on Wednesday, February 22, 2023 after market close, with a conference call to follow at 5:00 p.m. Eastern Time.

• FDA Announces Federal Court Enters Consent Decree Against Florida-based Drug Importer and Distributor

  1/30/2023

  The U.S. District Court for the Southern District of Florida entered a consent decree of permanent injunction against LGM Pharma LLC, an importer and distributor of active pharmaceutical ingredients, used by the company's customers to manufacture and/or compound finished drug products, and two of the company's executives, Chief Executive Officer and part owner, Prasad Raje, and Shailesh Vengurlekar, the company's Senior Vice President of Quality and Regulatory Affairs.

• Deka Biosciences Receives FDA Clearance of DK210 (EGFR) Investigational New Drug Application

  1/30/2023

  Deka Biosciences ("Deka"), a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the investigational new drug (IND) application for DK210 (EGFR) and concluded that Deka may proceed with a Phase 1 clinical trial in the United States.

• ClariMed, Inc Launches Integrated Medical Device Services Partner

  1/30/2023

  ClariMed, Inc., today announced the launch of the first MedTech services partner to take an integrated, human-centric approach to medical product development.